journal article·2022-10

Phase‐Transitional Bismuth‐Based Metals enable Rapid Embolotherapy, Hyperthermia, and Biomedical Imaging

Minghui Duan, Xiyu Zhu, Linlin Fan, Yuanyuan He, Chen Yang, Rui Guo, Sen Chen, Xuyang Sun, Jing Liu

Advanced Materials· Volume 34· Issue 42
Publisher page

Abstract

Abstract Embolization has been an important minimally invasive therapy for occlusion of malfunctioned vasculature and tumor treatment via target delivering embolic agents. The limitation of conventional embolic agents, such as fabrication process, precipitation time, invisibility, and lack of integrated functions often leads to insufficient embolization efficacy. To overcome these drawbacks, a multifunctional bismuth (Bi)‐based liquid embolic agent for simultaneous realization of embolotherapy, thermotherapy, as well as high‐contrast biomedical imaging is proposed. Benefitting from the suitable melting point, flexible nature, metallic merit, and easygoing operation via injection, the versatile embolic agent can achieve rapid liquid–solid phase transition, magnetic hyperthermia, and multimodal imaging capability. The Bi‐based materials are demonstrated with excellent arteriovenous embolization efficiency and favorable biocompatibility according to in vivo investigations. Introduction of the liquid embolic agent to tumor arteries achieves evident tumor regression and rather clear imaging under computed tomography (CT), magnetic resonance imaging (MRI), and thermographs for consistently tracking the implants over the biological body. Further, the combined therapy coupled with thermotherapy exhibits improved therapeutic efficiency with formation of necrosis and total tumor eradiation at day 15 after the treatment. The present innovative embolic agent and the surgical principle provide a promising modality for embolization and potential theranostic platform of tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Intracranial Aneurysms: Treatment and Complications · Catalysis and Oxidation Reactions · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering School of Medicine Tsinghua University Beijing 100084 China

School of Engineering Medicine Beihang University Beijing 100191 China

Technical Institute of Physics and Chemistry Chinese Academy of Sciences Beijing 100190 China

School of Physics Peking University Beijing 100871 China

School of Medicine Tsinghua University Beijing 100084 China

Department of Biomedical Engineering Tianjin University 92 Weijin Road Tianjin 300072 China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities

References (35)

Show source-provided references
1. 10.1002/adma.20190107110.1002/adma.201901071 ↗
2. 10.3174/ajnr.A520310.3174/ajnr.A5203 ↗
3. 10.1016/S0140-6736(05)67214-510.1016/S0140-6736(05)67214-5 ↗
4. 10.1021/acs.accounts.9b0028310.1021/acs.accounts.9b00283 ↗
5. 10.1067/j.cpradiol.2013.10.00310.1067/j.cpradiol.2013.10.003 ↗
6. 10.1155/2020/929585210.1155/2020/9295852 ↗
7. 10.1088/2516-1091/ab6c7d10.1088/2516-1091/ab6c7d ↗
8. 10.1016/j.colsurfa.2019.12436410.1016/j.colsurfa.2019.124364 ↗
9. 10.1002/adma.20211009410.1002/adma.202110094 ↗
10. 10.1002/adma.20210686510.1002/adma.202106865 ↗
11. 10.1136/neurintsurg-2017-01314410.1136/neurintsurg-2017-013144 ↗
12. 10.1016/j.mser.2019.03.00110.1016/j.mser.2019.03.001 ↗
13. 10.1016/j.apmt.2020.10072210.1016/j.apmt.2020.100722 ↗
14. 10.1021/acsami.8b0232010.1021/acsami.8b02320 ↗
15. 10.1002/adfm.20200335910.1002/adfm.202003359 ↗
16. 10.1016/j.apmt.2022.10149510.1016/j.apmt.2022.101495 ↗
17. 10.1002/adma.20200082710.1002/adma.202000827 ↗
18. 10.1002/smll.20190051110.1002/smll.201900511 ↗
19. 10.1002/smll.20190342110.1002/smll.201903421 ↗
20. 10.1021/acsnano.9b0484310.1021/acsnano.9b04843 ↗
21. 10.3390/mi1203028010.3390/mi12030280 ↗
22. 10.1016/j.tibtech.2020.10.00510.1016/j.tibtech.2020.10.005 ↗
23. 10.1016/j.matt.2020.08.02910.1016/j.matt.2020.08.029 ↗
24. 10.1039/D1NR01268A10.1039/D1NR01268A ↗
25. 10.1016/j.isci.2018.04.01210.1016/j.isci.2018.04.012 ↗
26. 10.1016/j.biomaterials.2014.08.04810.1016/j.biomaterials.2014.08.048 ↗
27. 10.1002/advs.20210071910.1002/advs.202100719 ↗
28. 10.1007/s11431-014-5583-410.1007/s11431-014-5583-4 ↗
29. 10.1002/adfm.20100251010.1002/adfm.201002510 ↗
30. 10.1002/jso.293025031710.1002/jso.2930250317 ↗
31. 10.1002/jmri.2132710.1002/jmri.21327 ↗
32. 10.1021/nn503719n10.1021/nn503719n ↗
33. Reginald K. A. · Sci. Transl. Med. · 2016 · 8 · 365ra156
34. DÜNne A. A. · Anticancer Res. · 2004 · 24 · 1785
35. 10.1007/s00280-008-0720-z10.1007/s00280-008-0720-z ↗